Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha CognitionFRA:7N70 -3.60%22 PB Ratio is 2.93 as of Jul. 16, 2026, which is 7% above its 10-year median of 2.75. GuruFocus rates FRA:7N70 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,227 Biotechnology companies, Alpha Cognition ranks worse than 52.4% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-16), Alpha Cognition's share price is €6.70. Alpha Cognition's Book Value per Share for the quarter that ended in Mar. 2026 was €2.28. Hence, Alpha Cognition's PB Ratio of today is 2.93.
The historical rank and industry rank for Alpha Cognition's PB Ratio or its related term are showing as below:
FRA:7N70'
s PB Ratio Range Over the Past 10 Years
Min: 1.62 Med: 2.75 Max: 5.43
Current: 3.13
During the past 6 years, Alpha Cognition's highest PB Ratio was 5.43. The lowest was 1.62. And the median was 2.75.
FRA:7N70's PB Ratio is ranked worse than 52.4% of 1227
companies
in the Biotechnology industry
Industry Median: 2.93
vs FRA:7N70: 3.13
During the past 12 months, Alpha Cognition's average Book Value Per Share Growth Rate was 3.60% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Alpha Cognition was -9.90% per year. The lowest was -9.90% per year. And the median was -9.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Alpha Cognition PB Ratio Related Terms
Alpha Cognition PB Ratio Historical Data
* Premium members only.
The historical data trend for Alpha Cognition's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alpha Cognition's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Cognition PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Cognition's PB Ratio distribution charts can be found below:
* The bar in red indicates where Alpha Cognition's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Alpha Cognition's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Alpha Cognition (FRA:7N70) has a PB Ratio of 2.93 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alpha Cognition and its competitors. This is near median its historical median of 2.75. Over the past decade, Alpha Cognition's PB Ratio has ranged from 1.62 to 5.43. According to the industry distribution chart, Alpha Cognition ranks #643 out of 1227 companies in the Biotechnology industry, placing it in the top 52.4%.
Is Alpha Cognition's PB Ratio too high?
Alpha Cognition's current PB Ratio of 2.93 is near median its 10-year median of 2.75. Over the past 10 years, this metric has ranged from a low of 1.62 to a high of 5.43. The Biotechnology industry median PB Ratio is 2.93. Alpha Cognition's value of 2.93 is 0% at this industry median. Based on the distribution chart, Alpha Cognition ranks #643 out of 1227 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alpha Cognition has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Cognition's PB Ratio compare to HURA and MENS?
According to the Biotechnology industry distribution chart, Alpha Cognition ranks #643 out of 1227 companies for PB Ratio. This places Alpha Cognition in the lower half of its industry. The industry median PB Ratio is 2.93. Alpha Cognition's value of 2.93 is 0% at this benchmark. Historically, Alpha Cognition's own PB Ratio has ranged from 1.62 to 5.43 over the past decade. While the company's 10-year median is 2.75 vs. the industry median of 2.93, Alpha Cognition has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpha Cognition's current PB Ratio of 2.93 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alpha Cognition and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Cognition's current PB Ratio is 2.93, which is near median its own 10-year median of 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Cognition stock overvalued right now?
Alpha Cognition (FRA:7N70) has a current PB Ratio of 2.93. The current PB Ratio is 2.93, which is near median its 10-year median of 2.75 and 0% at the Biotechnology industry median of 2.93. Alpha Cognition's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Alpha Cognition (FRA:7N70), the current PB Ratio is 2.93 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
22GF Score
Get the complete analysis for FRA:7N70
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7N70 has been successfully added to your 
